Israeli Innovation
Headquartered in Tel Aviv, Israel, Taffix® was developed and manufactured by Nasus Pharma, an innovative company in the development of intranasal powder-based products for a wide range of acute, life-threatening indications, where prompt treatment and speedy delivery is of the essence.
Prior to the current pandemic, we had already spent 3 years of R&D on different intranasal indications. In early 2020, when the magnitude of Covid-19 was becoming apparent, we immediately redirected all of our efforts to bring Taffix® to market as soon as possible. We wouldn’t have done it without the sleepless nights of all our team, and for that we will always be grateful.